ANCON Medical

ANCON Medical is a subsidiary of ANCON Technologies, specializing in non-invasive disease screening technology. The company's primary innovation, the Nanoparticle Biomarker Tagging (NBT), offers a highly sensitive breath screening device. Comprised of engineers, scientists, and business experts, ANCON Medical has developed the NBT technology and amassed a significant portfolio of patents and intellectual property in the U.S. and U.K. The technology is designed for compatibility with and deliverability to point-of-care clinics. The company's focus on providing unique healthcare solutions has enabled early detection of serious illnesses such as lung cancer and tuberculosis, emphasizing the importance of early diagnosis for effective treatment and improving patient outcomes. ANCON Medical has formed strong partnerships with global market leaders and reputable public and private laboratories, earning numerous grants and awards. In 2017, the company received a £965.00K investment in a Seed Round, showcasing confidence in their potential. ANCON Medical operates facilities in Minnesota, USA, as part of the state's Medcal Alley medical device manufacturing community, and in Kent, UK, within the Innovation Centre at the University of Kent at Canterbury. These strategic locations enable them to tap into diverse talent pools and research capabilities.